Navigation Links
Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
Date:7/22/2010

SOUTH SAN FRANCISCO, Calif., July 22 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) announced today that on July 20, 2010 it received a letter from the Nasdaq Stock Market stating that the minimum bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days and that the Company therefore is not in compliance with the minimum bid price requirement for continued listing set forth in Marketplace Rule [5450(a)(1)].  The notification of noncompliance has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Global Market.

The Company has been provided 180 calendar days, or until January 18, 2011, to regain compliance with the minimum bid price requirement.  To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for at least ten consecutive business days during this 180-day grace period.  Nasdaq may, in its discretion, require the Company's common stock to maintain a closing bid price of at least $1.00 for a period in excess of ten consecutive trading days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.

If the Company does not regain compliance by January 18, 2011, it will receive written notification from Nasdaq that its common stock is subject to delisting.  The Company may, at that time, appeal the delisting determination to a Nasdaq Hearings Panel.  Such an appeal, if granted, would stay delisting until a Panel ruling.  Alternatively, if at that time the Company satisfies all of the initial listing standards, with the exception of the minimum bid price, for the Nasdaq Capital Market, the Company could apply to transfer the listing of its common stock to the Nasdaq Capital Market and thereby receive an additional 180 calendar days to regain compliance with the minimum bid price requirement.

The Company will consider available options to resolve the minimum bid price deficiency and regain compliance with the Nasdaq minimum bid price requirement.  There can be no assurance that the Company will be able to regain or maintain compliance with the minimum bid price rule or other listing criteria or that an appeal, if taken, would be successful.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products. For additional information please visit http://www.poniard.com.

Forward Looking Statements

Statements made in this press release relating to future financial or business performance, conditions or strategies and other financial or business matters, including expectations and strategies regarding the Company's ability to comply with applicable listing standards, the Company's ability to transfer to the Nasdaq Capital Market and actions by Nasdaq.  These forward-looking statements are subject to certain assumptions, risks and uncertainties that could cause actual results and events to differ materially from the statements made.  Examples of such risks and uncertainties include:   the Company's ability to secure and maintain strategic partnerships to support the continued development of its picoplatin product candidate; the Company's anticipated future operating losses, need for future capital and ability to obtain future funding; the potential safety, efficacy and commercial viability of picoplatin; the risk that the Company's additional analyses of data  from clinical trials of picoplatin may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted trials; the receipt and timing of FDA and other regulatory approvals and actions; the Company's ability to retain key personnel; competition from third parties; the Company's ability to preserve and protect its intellectual property rights; the Company's dependence on third-party manufacturers, suppliers and other contractors; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2009.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2010 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
2. Poniard Pharmaceuticals Announces $6.3 Million Financing
3. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
4. Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference
5. Poniard Pharmaceuticals Announces Management Changes and Reduction in Force
6. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
7. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
8. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
9. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
10. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
11. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
(Date:5/12/2017)... Canada joint tech company Laughing Face has developed ... and features a powerful disinfection process. The company has ... and sanitizes women,s panties or babies, cloth diapers in 25 minutes. ... Laughing ... external water inlet. ...
(Date:5/10/2017)... , May 10, 2017 Radiology has ... unfortunately its costs have also spiraled to the number ... sent to radiology than ever before as the most ... For a patient with lower back pain an MRI ... anatomical reason for pain, resulting in entirely different treatment ...
Breaking Medicine Technology:
(Date:5/26/2017)... VA (PRWEB) , ... May 26, 2017 , ... ... pleased to announce a new educational seminar to focus on current legislative activity ... News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will continue ...
(Date:5/26/2017)... ... 2017 , ... Boar’s Head Brand®, one of the nation’s ... entertaining that are sure to satisfy your guests’ flavor cravings, while adding delicious ... featured in these refreshingly balanced recipes are packed with flavor, creating the perfect ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: ... the creation of published author Laura Weigel Douglas, an avid reader who lives in ... house that sometimes feels like Green Hills Adventure Camp. She couldn’t be more grateful. ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: the ... others. “Cactus Jack: Against All Odds” is the creation of published author, Walter ... is married to Jack Carlisle’s third child Jane. Walter. Walter and Jane have ...
Breaking Medicine News(10 mins):